MEDI4736

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerGastric CancerBladder CancerNon-Small Cell Lung CarcinomaUrothelial CancerCarboplatinOvarian

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

MEDI4736

AstraZeneca

Phase 3

32

Voltaren

Novartis

Preclinical

13

Lexiscan

Astellas

Preclinical

14

Methylthioninium Chloride

PProvepharm SAS

Preclinical

35

Tricor

JJagotec

Preclinical

16

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

17

Rilvegostomig

AstraZeneca

Preclinical

18

Vfend

PPrism Pharmaceuticals

Preclinical

—9

Ablavar

LLantheus Medical Imaging

Preclinical

210

4SCAR T Cells

SShenzhen Geno-Immune Medical Institute

Preclinical

1Show 15 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer5 trials

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Completed·AstraZeneca·Phase 3·NCT02125461·713 enrolled

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Completed·AstraZeneca·Phase 1·NCT02088112·56 enrolled

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

Completed·AstraZeneca·Phase 1·NCT02000947·459 enrolled

Show 2 more trials

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

Completed·SSwiss Cancer Institute·Phase 2·NCT02572843·68 enrolled

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer

Completed·CCanadian Cancer Trials Group·Phase 3·NCT02273375·1,415 enrolled

Squamous Cell Carcinoma3 trials

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Completed·AstraZeneca·Phase 2·NCT02319044·267 enrolled

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Completed·AstraZeneca·Phase 1/2·NCT02499328·340 enrolled

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed·AstraZeneca·Phase 2·NCT02207530·112 enrolled

Advanced Solid Tumours3 trials

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Completed·AstraZeneca·Phase 1·NCT02586987·58 enrolled

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Completed·AstraZeneca·Phase 1·NCT01938612·269 enrolled

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Completed·AstraZeneca·Phase 1·NCT02617277·56 enrolled

Breast Cancer3 trials

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Completed·YYale University·Phase 1/2·NCT02489448·68 enrolled

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer

Completed·GGBG Forschungs GmbH·Phase 2·NCT02685059·174 enrolled

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruiting·UUNICANCER·Phase 2·NCT02299999·1,460 enrolled

Advanced Solid Tumors2 trials

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Completed·KKyowa Kirin, Inc.·Phase 1·NCT02301130·64 enrolled

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Completed·AstraZeneca·Phase 1·NCT02261220·380 enrolled

25 more indications

Small Cell Lung Cancer2 trials

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Completed·AstraZeneca·Phase 2·NCT02087423·446 enrolled

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Completed·AstraZeneca·Phase 3·NCT02352948·597 enrolled

Head and Neck Cancer2 trials

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

Completed·AstraZeneca·Phase 3·NCT02369874·736 enrolled

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

Completed·AstraZeneca·Phase 1·NCT02262741·71 enrolled

Malignant Pleural Mesothelioma1 trial

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Completed·—·Phase 2·NCT02592551·24 enrolled

Bladder Cancer1 trial

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Active, not recruiting·AstraZeneca·Phase 1·NCT02546661·117 enrolled

Lymphoma1 trial

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Completed·PPharmacyclics LLC.·Phase 1/2·NCT02401048·61 enrolled

Monotherapy1 trial

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

Completed·AstraZeneca·Phase 3·NCT02454933·29 enrolled

Relapsed/Refractory1 trial

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Completed·AstraZeneca·Phase 1·NCT02549651·32 enrolled

Colorectal Cancer1 trial

Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02227667·16 enrolled

Metastasis1 trial

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Terminated·WWashington University School of Medicine·Phase 2·NCT02669914·4 enrolled

Mesothelioma1 trial

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Completed·AstraZeneca·Phase 1·NCT02141347·65 enrolled

Gastrointestinal1 trial

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Completed·Eli Lilly·Phase 1·NCT02572687·85 enrolled

Metastatic Melanoma1 trial

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Completed·—·Phase 1·NCT02639026·53 enrolled

Renal Cell Carcinoma1 trial

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

Completed·QQueen Mary University of London·Phase 2·NCT02819596·69 enrolled

Pancreatic Cancer1 trial

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Withdrawn·NNYU Langone Health·Phase 1·NCT02868632

Phase 11 trial

A Phase 1/2 Study to Evaluate MEDI4736

Completed·AstraZeneca·Phase 1/2·NCT01693562·1,022 enrolled

Carboplatin1 trial

Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

Active, not recruiting·JJules Bordet Institute·Phase 1/2·NCT03616886·129 enrolled

Papilloma1 trial

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Terminated·AAdvaxis, Inc.·Phase 1/2·NCT02291055·75 enrolled

Adenocarcinoma1 trial

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

Completed·AstraZeneca·Phase 1/2·NCT02340975·114 enrolled

Advanced Solid Malignancies1 trial

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

Completed·AstraZeneca·Phase 3·NCT03084471·867 enrolled

Metastatic Head and Neck Cancer1 trial

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

Completed·AstraZeneca·Phase 3·NCT02551159·823 enrolled

Selected Advanced Solid Tumors1 trial

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Completed·Incyte·Phase 1/2·NCT02318277·176 enrolled

Gastric Cancer1 trial

Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Active, not recruiting·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT02678182·494 enrolled

Non-Small Cell Lung Carcinoma1 trial

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).

Active, not recruiting·AstraZeneca·Phase 3·NCT02453282·1,118 enrolled

Ovarian1 trial

A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors

Active, not recruiting·AstraZeneca·Preclinical·NCT02734004·264 enrolled

Urothelial Cancer1 trial

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer

Active, not recruiting·AstraZeneca·Phase 3·NCT02516241·1,126 enrolled

Details

Drug Info

Related News